NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today posted an overview of new data on BMS-901608 on the company website. BMS-901608 is an anti-CS-1 antibody under investigation for the treatment of multiple myeloma in Phase II development. The data were presented Sunday, June 6, at the American Society of Clinical Oncology (ASCO) 2010 meeting in Chicago.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
Bristol-Myers Squibb CompanyMedia:Jennifer Fron Mauer, 609-252-6579jennifer.mauer@bms.comorInvestors:John Elicker, 609-252-4611john.elicker@bms.com